Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SIFI Receives European Commission Approval for AKANTIOR®
Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that got approval from european medicines agency for the treament of acanthamoeba keratitis.
Brand Name : Akantior
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 26, 2024
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SIFI Receives Positive Opinion for Orphan Drug Designation for Polihexanide
Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.
Brand Name : Akantior
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 22, 2024
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Avanzanite’s AKANTIOR® Gets Positive CHMP Opinion and Expands into 26 European Countries
Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.
Brand Name : Akantior
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 03, 2024
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SIFI Receives Positive CHMP Opinion for AKANTIOR in Acanthamoeba Keratitis
Details : Akantior® (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.
Brand Name : Akantior
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 31, 2024
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Avanzanite Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Sifi Announces License Agreement with Avanzanite Bioscience for Akantior®
Details : AKANTIOR® (polihexanide) is an investigational anti-amoebic polymer that has been granted Orphan Drug Designation by both the European Medicines Agency ("EMA") and Food and Drug Administration ("FDA") for AK.
Brand Name : Akantior
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 10, 2023
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Avanzanite Bioscience
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : 87% of patients receiving AKANTIOR® in the Phase 3 Trial were medically cured within a median duration of 4 months compared to 55% with the treatment protocols used in real-world clinical practice today.
Brand Name : Akantior
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 13, 2022
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Study Phase : Approved
Recipient : Alimera Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Alimera Announces Approval and Pricing Granted for ILUVIEN for Uveitis in Italy
Details : ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant, injected into back of eye,is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for 36 months, to reduce recurrence o...
Brand Name : Iluvien
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 08, 2022
Lead Product(s) : Fluocinolone Acetonide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Recipient : Alimera Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Durbin
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AKANTIOR® (polihexanide) stands to become first approved drug for the treatment of acanthamoeba keratitis in the world. It is an anti-amoebic polymer that acts on both the trophozoites and cysts of the protozoan Acanthamoeba.
Brand Name : Akantior
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 07, 2022
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Durbin
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world. Polihexanide, a New Chemical Entity (NCE), is an anti-amoebic polymer that acts on both the trophozoites and cysts of the protozoan...
Brand Name : Akantior
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 16, 2022
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Progesterone
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SIFI Initiates Patient Enrollment in Phase II Trial evaluating Pro-Ocular in Dry Eye Disease
Details : ProGIFT is a multicenter, randomized, double-masked, placebo-controlled Phase II clinical trial comparing different concentrations of Pro-ocular (1% and 0.5%) versus placebo.
Brand Name : Pro-ocular
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 27, 2021
Lead Product(s) : Progesterone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?